Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.86 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | APLNR | P35414 | 4/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL7751433 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL6448301 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| SCHEMBL21109135 | 0.98 | GNRHR (0.84) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3975990-A1 | LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER | Tolmar International Limited (IE) | 2022-04-06 | — | — | EP | claimed |
| CN-114144169-A | Leuprolide acetate compositions and methods of using same for treating breast cancer | 托尔玛国际有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2020240417-A1 | LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER | TOLMAR INTERNATIONAL LIMITED (IE) | 2020-12-03 | — | — | WO | claimed |
| CN-118320058-A | Pharmaceutical composition with selected duration of release | 逸达生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-111511385-B | Pharmaceutical composition with selected duration of release | 逸达生物科技股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4319790-A1 | METHODS OF TREATMENT OF PEDIATRIC PUBERTY USING ORAL FORMULATIONS OF LEUPROLIDE | Enteris BioPharma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230355511-A1 | BIODEGRADABLE POLYMER AND SOLVENT COMPOSITIONS AND SYSTEMS FOR EXTENDED STORAGE AND DELIVERY OF ACTIVE PHARMACEUTICAL INGREDIENTS | TOLMAR INTERNATIONAL LIMITED (IE) | 2023-11-09 | — | — | US | disclosed |
| US-20230346877-A1 | Pharmaceutical Compositions having a Selected Release Duration | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-11-02 | — | — | US | disclosed |
| EP-4221688-A1 | BIODEGRADABLE POLYMER AND SOLVENT COMPOSITIONS AND SYSTEMS FOR EXTENDED STORAGE AND DELIVERY OF ACTIVE PHARMACEUTICAL INGREDIENTS | Tolmar International Limited (IE) | 2023-08-09 | — | — | EP | disclosed |
| US-11717555-B2 | Pharmaceutical compositions having a selected release duration | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-08-08 | — | — | US | disclosed |
| CN-114364399-A | Combination therapy of semaphorin-4D blocker (SEMA4D) with DC1 therapy | 瓦西尼斯公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20160331802-A1 | Pharmaceutical Compositions with Enhanced Stability | LI YUHUA (US) | 2016-11-17 | — | — | US | disclosed |
| EP-1984009-B1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY | QPS LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-1984009-A4 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY | QPS LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2029111-A2 | MICROPARTICLES AND METHODS FOR PRODUCTION THEREOF | Baxter International Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1984009-A2 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY | QPS, LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007143381-A2 | MICROPARTICLES AND METHODS FOR PRODUCTION THEREOF | BAXTER INTERNATIONAL INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281031-A1 | Microparticles and methods for production thereof | BAXTER HEALTHCARE S.A. (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20070196416-A1 | Pharmaceutical compositions with enhanced stability | QUEST PHARMACEUTICAL SERVICES (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007084460-A2 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY | QPS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |